A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010
Public Engagement To compare the efficacy of JM-010 (administered as 2 different dose combinations of buspirone and zolmitriptan) to that of
placebo therapy in reducing dyskinesia severity in PD by evaluating the mean change from Baseline to Week 12 on the
Unified Dyskinesia Rating Scale (UDysRS).